VeracyteVCYT
About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Employees: 824
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
30% more call options, than puts
Call options by funds: $48K | Put options by funds: $37K
4% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 97
0.2% less ownership
Funds ownership: 108.5% [Q1] → 108.3% (-0.2%) [Q2]
5% less funds holding
Funds holding: 285 [Q1] → 271 (-14) [Q2]
9% less capital invested
Capital invested by funds: $2.51B [Q1] → $2.29B (-$215M) [Q2]
18% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 45
100% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 0 (-3) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for VCYT.
Financial journalist opinion
Based on 10 articles about VCYT published over the past 30 days
